PACT Antibody (D-4): sc-377103

PACT Antibody (D-4) is a mouse monoclonal IgG2a kappa light chain antibody that detects PACT protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry, and enzyme-linked immunosorbent assay (ELISA). PACT (D-4) antibody is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. PACT protein, also known as interferon-inducible double-stranded RNA-dependent protein kinase activator or PKR-associated protein X, plays a crucial role in cellular response to stress by activating protein kinase PKR. This activation leads to eIF2α phosphorylation, which inhibits protein translation and can trigger apoptosis, making PACT an important player in regulating cell survival under adverse conditions. PACT can directly bind to double-stranded RNA, although pro-apoptotic function is enhanced in absence of dsRNA. Growth factors can inhibit PACT′s apoptotic activity, highlighting regulatory role in cell fate decisions. In human and mouse cells, PACT undergoes phosphorylation at Serine 18, and this phosphorylated form is essential for PKR activation following stress. PACT may form a heterodimer with eIF2α, interacting through double-stranded RNA binding motif domain, which underscores significance in stress response pathway.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

PACT Antibody (D-4) References:

1. RAX, a cellular activator for double-stranded RNA-dependent protein kinase during stress signaling.  |  Ito, T., et al. 1999. J Biol Chem. 274: 15427-32. PMID: 10336432
2. The C-terminal, third conserved motif of the protein activator PACT plays an essential role in the activation of double-stranded-RNA-dependent protein kinase (PKR).  |  Huang, X., et al. 2002. Biochem J. 366: 175-86. PMID: 11985496
3. Inhibition of PACT-mediated activation of PKR by the herpes simplex virus type 1 Us11 protein.  |  Peters, GA., et al. 2002. J Virol. 76: 11054-64. PMID: 12368348
4. A novel role for RAX, the cellular activator of PKR, in synergistically stimulating SV40 large T antigen-dependent gene expression.  |  Yang, M., et al. 2003. J Biol Chem. 278: 38325-32. PMID: 12874289
5. Serine 18 phosphorylation of RAX, the PKR activator, is required for PKR activation and consequent translation inhibition.  |  Bennett, RL., et al. 2004. J Biol Chem. 279: 42687-93. PMID: 15299031
6. DYT16, a novel young-onset dystonia-parkinsonism disorder: identification of a segregating mutation in the stress-response protein PRKRA.  |  Camargos, S., et al. 2008. Lancet Neurol. 7: 207-15. PMID: 18243799
7. A heterozygous frameshift mutation in PRKRA (DYT16) associated with generalised dystonia in a German patient.  |  Seibler, P., et al. 2008. Lancet Neurol. 7: 380-1. PMID: 18420150
8. PRKRA Mutation Causing Early-Onset Generalized Dystonia-Parkinsonism (DYT16) in an Italian Family.  |  Quadri, M., et al. 2016. Mov Disord. 31: 765-7. PMID: 26990861
9. Deep Brain Stimulation in Patients with Isolated Generalized Dystonia Caused by PRKRA Mutation.  |  Casagrande, SCB., et al. 2019. Mov Disord Clin Pract. 6: 616-618. PMID: 31538099
10. Imaging Evidence of Nigrostriatal Degeneration in DYT-PRKRA.  |  Pinto, MJ., et al. 2020. Mov Disord Clin Pract. 7: 472-474. PMID: 32373670
11. Uniparental disomy screen of Irish rare disorder cohort unmasks homozygous variants of clinical significance in the TMCO1 and PRKRA genes.  |  Molloy, B., et al. 2022. Front Genet. 13: 945296. PMID: 36186440
12. PACT, a protein activator of the interferon-induced protein kinase, PKR.  |  Patel, RC. and Sen, GC. 1998. EMBO J. 17: 4379-90. PMID: 9687506

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-PACT Antibody (D-4) has 12 citations in a variety of scientific publications.

Primary antibodies like Anti-PACT Antibody (D-4) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

PACT Antibody (D-4) Specifications

Alternate Product Name: PACT

Product Clone Name: D-4

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG_2a kappa light chain

Amino Acids: 137-173

Epitope Target: PACT

Epitope Species: human

Product Reactivity/Detection: PACT

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: equine, canine, bovine and porcine

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), ELISA

Vialing Information: Each vial contains 200 µg IgG_2a kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 12 citations in various scientific publications

Available Conjugates/Forms for PACT Antibody (D-4): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, P: Blocking Peptide, PE: Phycoerythrin